<DOC>
	<DOCNO>NCT01022047</DOCNO>
	<brief_summary>To assess efficacy study product Noex treatment allergic rhinitis mean Nasal Index Score ( NIS ) 4 week treatment drug .</brief_summary>
	<brief_title>Non-inferiority , Open-label , Multicenter Randomized Clinical Trial About Treatment Mild Moderate Persistent Allergic Rhinitis</brief_title>
	<detailed_description>Primary objective : To assess efficacy study product Noex treatment allergic rhinitis mean Nasal Index Score ( NIS ) 4 week treatment drug . Secondary objective : To determine total NIS scale score 12 week treatment score scale individually symptoms nasal obstruction , coryza , sneeze nasal pruritus 4 12 week treatment , well assess safety study product accord presence adverse event . Some eligibility criterion : - NIS scale score &gt; 4 point randomization visit - Patients persistent mild moderate AR , accord ARIA criterion indication use budesonide ;</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Sign inform consent form case patient young 18 year , legal responsible must sign consent ; â‰¥ 12 year old ; NIS scale score &gt; 4 point randomization visit Patients persistent mild moderate AR , accord ARIA criterion ( see Appendix B ) , indication use budesonide ; Positive skin test least one relevant airborne agent ; AR symptoms least 2 year ; May undergo washout period least 2 week ( without use oral , nasal inhalant corticosteroid agent ; see 6.4 ) . Patients persistent severe allergic rhinitis ; Patients severe comorbidities ( investigator 's opinion ) ; Patients moderate severe persistent asthma ; Clinical history infection airways 30 day study entry ; Patients structural change cause nasal obstruction , pronounce nasal septum deviation , nasal polyp type nasal malformation ; Pregnant woman patient plan become pregnant study period breastfeed woman ; Patients need drug treat allergic rhinitis , antiimmunoglobulin E , allergenspecific immunotherapy , antileukotrienes , systemic vasoconstrictor , oral corticosteroid inhalant corticosteroid . Patients use allergenspecific immunotherapy last year , well use antileukotrienes antiimmunoglobulin E last month , even patient use inhalant oral corticosteroid V0 enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>